

## WADA Technical Letter – TL07

Document Number:	TL07 (replaces TL06/2016)	Version Number:	2.0
Written by:	WADA LabEG	Approved by:	WADA LabEG*
Date:	17 August 2016	Effective Date:	17 August 2016

\*The approval by the WADA Executive Committee is applicable only to Technical Letters issued after November 2019.

### ANDARINE - FLUTAMIDE

The *World Anti-Doping Agency* wishes to draw the attention of the Laboratories to the following remarks and instructions on the analysis and reporting of **andarine metabolite O-dephenylandarine**.

Scientific information and technical developments indicate that O-dephenylandarine, a *Metabolite* of the SARM andarine, may also be present in a *Sample* as a *Metabolite* of the anti-androgen **flutamide**. Since flutamide is not a *Prohibited Substance* in sports, it is essential for Laboratories to be in a position to accurately identify the original source of O-dephenylandarine.

Therefore, we strongly recommend that your Laboratory reviews in the shortest delay the case recently reported by L. Perrenoud *et al.* entitled “**Risk of false positive results to SARM S-4 in case of 1 therapeutic use of 2 antineoplastic/antiandrogen drug containing flutamide: a case study**” in Drug Testing and Analysis (available online at <http://onlinelibrary.wiley.com/doi/10.1002/dta.2051/full>) in order to implement the requisite methodology to correctly interpret the origin of O-dephenylandarine and appropriately report the *Adverse Analytical Findings* coming from andarine and not from flutamide.

Should you have any further questions, please do not hesitate to contact the WADA Science Department.